Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
Clinical Data launches PGxPredict:Rituximab on schedule
February 27th, 2007
Clinical Data, Inc. (CLDA) announced that its PGxHealth division, provider of Therapeutic Diagnostics, has launched a new test, PGxPredict:Rituximab, further strengthening its leadership position within the rapidly evolving fields of pharmacogenetics and molecular diagnostics. This is the second pharmacogenetic test of its kind launched by PGxHealth in recent months. The assay is based on a worldwide exclusive license to an intellectual property portfolio from Innate Pharma S.A. of Marseille, France. PGxPredict:Rituximab is a pharmacogenetic test that helps physicians predict the likelihood of a given patient responding to rituximab monotherapy in...
Source: Cancer Weekly (2007-02-27)
|
